Psychedelic Therapy for PTSD: MDMA vs Ketamine vs Psilocybin

Four psychedelic-adjacent substances now have some research base in PTSD: MDMA, ketamine, psilocybin, and ibogaine. They are not interchangeable. Each sits at a different point on evidence strength, legal access, and how far along its own research program actually is. Podcast guests and forum threads often talk about "psychedelics for PTSD" as one category. Treating it as one category is the first mistake.

This guide sorts the four by what the trials actually show, what is legally available right now, and where the access gap sits. Every claim links to a deeper substance-specific guide with the full study detail.

The evidence map: four substances, four different stories

MDMA: the strongest trial evidence, still not approved

MDMA-assisted therapy has the most direct PTSD evidence of any psychedelic. Mitchell et al. reported two positive Phase 3 trials in Nature Medicine (2021 and 2023), and the sponsor's original protocol paired three MDMA sessions with structured psychotherapy. The FDA nonetheless declined to approve the therapy, issuing a Complete Response Letter in August 2024 and asking for an additional trial. As of this writing, the sponsor has resubmitted its application rather than run a new Phase 3 study. None of that changes today's legal reality: MDMA is Schedule I, and outside a trial or FDA Expanded Access, therapeutic use is not legal in the US. See the MDMA guide for the full trial history, the FDA's specific concerns, and current trial enrollment.

Ketamine: legally accessible, evidence is mixed

Ketamine is the only substance on this page a US clinician can prescribe for PTSD today without a trial. That access comes with a caveat: the PTSD-specific evidence is inconsistent. An early positive single-site trial and several smaller replications exist alongside a larger 2024 VA trial that did not find a benefit over placebo. Spravato (esketamine), the one FDA-approved ketamine-class product, is approved for treatment-resistant depression, not PTSD; VA coverage of it follows the depression indication, not a PTSD one. See the ketamine guide for the full evidence review and ketamine therapy for veterans for the veteran-specific access picture.

Psilocybin: borrowed evidence, not direct proof

Psilocybin's PTSD case is built by inference. The compound carries FDA Breakthrough Therapy designation for depression, and depression is highly comorbid with PTSD, so researchers and clinicians reasonably ask whether the depression-trial benefit might transfer. No completed randomized trial has tested psilocybin against PTSD as the primary diagnosis. Oregon (Measure 109) and Colorado (Prop 122) let adults access supervised psilocybin sessions, but those programs are adult-use models, not a PTSD treatment pathway, and centers are not required to screen or treat for a specific diagnosis. See the psilocybin guide for what the depression and anxiety evidence actually shows.

Ibogaine: the newest PTSD research entrant

Ibogaine's addiction evidence is stronger than its PTSD evidence, but PTSD is now explicitly part of its research pipeline. Texas appropriated $50 million in 2025 for the IMPACT consortium, led by UTHealth Houston and UTMB Health, to pursue FDA-authorized trials in opioid use disorder, traumatic brain injury, and PTSD together, reflecting how often those three co-occur in veterans. Observational reports from special-operations veterans treated at international clinics describe PTSD symptom relief alongside the addiction and TBI outcomes, though that evidence is observational, not randomized. See best ibogaine treatment centers for reviewed international options and ibogaine for opioid addiction for the trial and safety detail shared across both indications.

Psychedelic-assisted therapy vs. standard PTSD care

Standard-of-care PTSD treatment is trauma-focused psychotherapy (prolonged exposure, cognitive processing therapy, EMDR) and, where medication is used, SSRIs such as sertraline and paroxetine, the only two FDA-approved drugs for PTSD. That remains the recommended starting point for most patients: it is broadly covered, has a decades-long safety record, and does not require travel or trial enrollment.

Psychedelic-assisted therapy is most relevant when standard care has already been tried without enough benefit, or when a patient qualifies for an enrolling trial. It is not positioned, in any of the research programs above, as a first-line replacement for trauma-focused therapy or SSRIs.

How to access legally in 2026

1. Clinical trials. MDMA, ketamine, and ibogaine trials for PTSD are enrolling at various sites, including the Texas IMPACT consortium. Use the clinical trial finder to search by indication and location.
2. Legally accessible ketamine. A licensed clinician can prescribe ketamine off-label for PTSD today. Use the ketamine provider finder to identify programs that treat trauma, not only depression.
3. FDA Expanded Access. Individual patients with a treating physician can, in limited cases, request MDMA outside a trial through FDA Expanded Access; this requires physician sponsorship and case-by-case FDA authorization, and is not a routine pathway.
4. International clinics. Ibogaine centers in Mexico and Costa Rica operate legally in those countries and treat US patients, though PTSD-specific outcome data from these clinics remains observational.

Access for veterans specifically

Veterans have a wider set of PTSD-focused options than civilians, because several programs exist specifically for post-9/11 service members. VETS (Veterans Exploring Treatment Solutions) is a nonprofit that grants funding for ketamine and other psychedelic therapy for eligible veterans. The VA covers Spravato at VA facilities under the Mission Act, though that coverage follows the treatment-resistant-depression indication and availability varies by location. The Texas IMPACT ibogaine trial was itself designed around veterans with co-occurring PTSD and TBI. See ketamine therapy for veterans for the full breakdown of VETS eligibility, VA Spravato coverage, and provider options.

Who this is not for

Screening exists for real safety reasons, and it is broadly similar across all four substances:

• Active psychosis or a personal/family history of a psychotic disorder: a hard exclusion for MDMA, psilocybin, and ibogaine trials.
• Pre-existing cardiac disease: a hard exclusion for ibogaine specifically, due to QT-prolongation risk.
• Bipolar I disorder: excluded from virtually every current MDMA and psilocybin trial.
• Pregnancy.
• Certain SSRI/MAOI combinations: MDMA and ibogaine both carry serotonin-syndrome risk with SSRIs and MAOIs; ketamine interactions are generally milder but should still be reviewed with a prescriber.
• Acute, unstabilized crisis: active suicidality or a recent trauma event should be stabilized with standard care first.

See the psychedelic medication safety guide for the full contraindication and medication-interaction list.

Bottom line

No psychedelic is FDA-approved for PTSD in 2026. MDMA has the strongest trial evidence but the least legal access; ketamine has the most legal access but the least consistent evidence; psilocybin's PTSD case is inferred, not proven; and ibogaine is the newest entrant, with PTSD named directly in a major US trial for the first time. The right starting point depends on whether standard-of-care therapy and SSRIs have already been tried, whether a trial is enrolling nearby, and, for veterans, whether a VETS grant or VA program applies.

Not sure where to start? Our which psychedelic quiz maps your situation to the option with the strongest evidence for your goal, and the clinical trial finder shows what is enrolling now. If you or someone you know is in active crisis, please see the crisis resources page first.